Search Results
Feb 13, 2026, 02:28 ET World-First EXO 001 Exosome Platform Enables In Vivo Multi-Target CAR-T for Solid Tumors
evaluation.Following intravenous administration, EXO 001 circulates through key immune organs such as the spleen, where it precisely delivers Nb-CAR.BiTE genes to CD3-positive T cells. This enables direct genetic programming within the patient's body, converting native T cells into multi-target CAR-T cells capable
More news about: China Medical University Hospital
Feb 13, 2026, 01:04 ET HanchorBio Receives FDA Orphan Drug Designation for HCB101 in Gastric Cancer
the CD47–SIRPα innate immune checkpoint while minimizing hematologic toxicity. Unlike earlier anti-CD47 approaches, HCB101 is designed to preserve macrophage-mediated antitumor activity while reducing binding to red blood cells, a limitation that historically constrained the clinical utility of CD47-directed
More news about: HanchorBio Inc.
Feb 12, 2026, 18:56 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA
with Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD), who have received at least one prior therapy including an anti-CD20 containing regimen." Atara said that "[t]he CRL indicates that the FDA is unable to approve the EBVALLO™ BLA in its present form" because, according
More news about: Pomerantz LLP
Feb 12, 2026, 15:30 ET LA COMMISSION EUROPEENNE APPROUVE UPLIZNA® D'AMGEN DANS LE CADRE DU TRAITEMENT DE LA MYASTHÉNIE GRAVE GÉNÉRALISÉE
Première et seule thérapie ciblant le CD19, approuvée en Europe pour les adultes atteints de MGg anti-AChR+ et anti-MuSKUPLIZNA démontre une maîtrise durable de la maladie avec une posologie biannuelle*THOUSAND
More news about: Amgen
Feb 12, 2026, 15:15 ET La Comisión Europea aprueba UPLIZNA® de Amgen para la miastenia gravis generalizada
Primera y única terapia dirigida a CD19 aprobada en Europa para adultos con gMG anti-AChR+ y anti-MuSK+UPLIZNA demuestra un control duradero de la enfermedad con una dosificación semestral*THOUSAND OAKS, California,
More news about: Amgen
Feb 12, 2026, 09:00 ET EUROPEAN COMMISSION APPROVES AMGEN'S UPLIZNA® FOR GENERALIZED MYASTHENIA GRAVIS
First and Only CD19-Targeted Therapy Approved in Europe for Adults with anti-AChR+ and anti-MuSK+ gMGUPLIZNA Demonstrates Durable Disease Control with Twice-Yearly Dosing*THOUSAND OAKS, Calif., Feb.
More news about: Amgen
Feb 12, 2026, 08:05 ET INOVIO to Participate in Upcoming Scientific and Investor Conferences
Session APoster Presentation: Treatment of RRP with DNA immunotherapy INO-3107 induces activation and enrichment of pro-inflammatory CD4+ T cell responses in blood and airways of patients with clinical responseOppenheimer 36th Annual Healthcare Life Sciences Conference
More news about: INOVIO Pharmaceuticals, Inc.
Feb 12, 2026, 08:00 ET Black Duck Expands Polaris Integrations to Deliver Frictionless DevSecOps at Enterprise Scale
in the SDLC.Apply AI‑powered application security with Black Duck Signal™. Enabling scans directly in the IDE or automated through CI/CD, all centrally managed in Polaris. Signal surfaces meaningful security insights in both human‑ and AI‑generated code, helping teams stop vulnerabilities
More news about: Black Duck Software
Feb 12, 2026, 07:30 ET Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress
all-oral combination of selinexor 40 mg, pomalidomide and dexamethasone (SPd40) in patients with previously treated multiple myeloma who received an anti-CD38 in their immediate prior line of therapy.Anticipated Catalysts and Operational ObjectivesMyelofibrosis Top-line
More news about: Karyopharm Therapeutics Inc.
Feb 12, 2026, 07:00 ET ECARX Announces Fourth Quarter 2025 Unaudited Financial Results
https://register-conf.media-server.com/register/BI77be73bf981b49c7bed9cd333bdda80e to receive dial-in information.A replay of the webcast and presentation materials will be available
More news about: ECARX Holdings Inc.
Feb 11, 2026, 08:30 ET Constructive Launches Secure-by-Default Postgres Platform for the Agentic Era
deterministic migrations produce identical outputs, making guarantees reproducible and verifiable. Authorization remains testable end to end, with CI/CD pipelines validating RLS so traditionally opaque security logic becomes verifiable code. Constructive also includes a built-in, language-agnostic serverless
More news about: Constructive
Feb 11, 2026, 08:00 ET Black Duck Announces MSSP Agreement with Accenture, Combining World-Class Application Security Technology and Services
platform.Ease of Use: Simple onboarding, deployment, and testing with seamless integrations into development, test automation, and CI/CD workflows.Scalability: Cost-effective scaling to meet the needs of organizations, from testing a single application to thousands.Risk
More news about: Black Duck Software
Feb 11, 2026, 06:07 ET Molecule Found to Drive Skin Cancer Growth and Evade Immune Detection
that increase blood supply to tumors (angiogenesis), including those involving vascular endothelial growth factor (VEGF), semaphorin-3A (SEMA3A), and CD73. Experiments in which they suppressed HOXD13 activity led to tumor shrinkage.The researchers also found that blood levels of cytotoxic T cells,
More news about: NYU Langone Health System
Feb 10, 2026, 13:00 ET Becton, Dickinson and Company Announces Tender Offers for Outstanding Debt Securities
Registered: 075887CE7144A: 075887CD9Reg S: U0740RAE2
More news about: BD (Becton, Dickinson and Company)
Feb 10, 2026, 07:57 ET Finalists Announced for RSAC Innovation Sandbox Contest 2026
Crash OverrideCrash Override embeds in CI/CD to capture build execution data that APIs can't access, prove what's deployed with automated SLSA Level-2 compliance, complete provenance tracking, and
More news about: RSAC
Feb 10, 2026, 06:00 ET Gyala Therapeutics initiates Phase I/IIa clinical trial of a CAR-T cell therapy in acute leukemias with limited treatment options
GYA01, a first-in-class CAR-T cell therapy targeting the CD84 protein, in patients with relapsed or refractory acute myeloid leukemia (AML) or T-cell acute lymphoblastic leukemia (T-ALL), diseases with poor prognosis and limited treatment options. CD84 is an emerging therapeutic target characterized by high
More news about: Gyala Therapeutics
Feb 10, 2026, 06:00 ET Gyala Therapeutics startet Phase-I/IIa-Studie zu einer CAR-T-Zelltherapie bei akuten Leukämien mit begrenzten Behandlungsoptionen
erste ihrer Klasse, die auf das CD84-Protein abzielt, bei Patienten mit rezidivierter oder refraktärer akuter myeloischer Leukämie (AML) oder T-Zell-akuter lymphoblastischer Leukämie (T-ALL), zwei Erkrankungen mit ungünstiger Prognose sowie begrenzten Behandlungsoptionen. CD84 ist ein neu aufkommendes therapeutisches
More news about: Gyala Therapeutics
Feb 10, 2026, 06:00 ET Gyala Therapeutics initiates Phase I/IIa clinical trial of a CAR-T cell therapy in acute leukemias with limited treatment options
GYA01, a first-in-class CAR-T cell therapy targeting the CD84 protein, in patients with relapsed or refractory acute myeloid leukemia (AML) or T-cell acute lymphoblastic leukemia (T-ALL), diseases with poor prognosis and limited treatment options. CD84 is an emerging therapeutic target characterized by high
More news about: Gyala Therapeutics
Feb 10, 2026, 06:00 ET Gyala Therapeutics inicia un ensayo clínico de fase I/IIa de una terapia con células CAR-T
terapia celular CAR-T pionera dirigida a la proteína CD84, en pacientes con leucemia mieloide aguda (LMA) o leucemia linfoblástica aguda de células T (T-ALL) en recaída o refractaria, enfermedades con mal pronóstico y limitadas opciones de tratamiento. CD84 es una diana terapéutica emergente que se caracteriza
More news about: Gyala Therapeutics
Feb 10, 2026, 06:00 ET Gyala Therapeutics lance un essai clinique de phase I/IIa évaluant une thérapie cellulaire CAR-T dans les leucémies aiguës pour lesquelles les options thérapeutiques sont limitées
CAR-T pionnière ciblant la protéine CD84, chez des patients atteints de leucémie myéloïde aiguë (LMA) ou de leucémie lymphoblastique aiguë à cellules T (LLA-T) récidivante ou réfractaire, des maladies au pronostic défavorable et aux options thérapeutiques limitées. Le CD84 est une cible thérapeutique émergente
More news about: Gyala Therapeutics
Feb 10, 2026, 02:02 ET A college student's virtual game becomes a global conspiracy in CD Miles' techno-thriller 'Dark Agenda'
Agenda"By CD MilesHardcover | 5.5 x 8.5in | 144 pages | ISBN 9798369440247Softcover | 5.5 x 8.5in | 144 pages | ISBN 9798369440254E-Book | 144 pages | ISBN 9798369440230Available at Amazon and Barnes & NobleAbout the AuthorCD Miles has been
More news about: Xlibris
Feb 09, 2026, 10:40 ET Data Warehouse Automation Software Market Fueled by Rising Demand for Faster Data Integration, Cloud Adoption, and AI-Driven Analytics Workflows: Market Research Intellect
agile practices is reshaping the Data Warehouse Automation Software Market. Automation tools support continuous integration and continuous deployment (CI/CD) pipelines, enabling faster testing, version control, and deployment of data warehouse components. This approach enhances collaboration between development
More news about: Market Research Intellect
Feb 09, 2026, 07:00 ET Lilly to acquire Orna Therapeutics to advance cell therapies
to allow the patient's own body to generate cell therapies that can treat underlying disease. Orna's lead program is ORN-252, a clinical trial-ready, CD19 targeting in vivo Chimeric Antigen Receptor T-cell (CAR-T) therapy designed to treat B cell-driven autoimmune diseases. Experiments to date
More news about: Eli Lilly and Company
Feb 06, 2026, 10:10 ET February 2026 CD Rates: CD Valet Reveals How Financial Institutions are Leveraging CDs as a Growth Engine Amid Economic Uncertainty
Roske.About CD Valet CD Valet is a CD marketplace that features verified CD rates from federally insured banks and credit unions nationwide. With tens of thousands of CD offers tracked across the country, CD Valet gives savers a clear view of top rates and helps them explore higher-yield CD options
More news about: CD Valet
Feb 06, 2026, 10:00 ET EverBank Launches 2026 Draft Night Experience Sweepstakes
2026, eligible sweepstakes participants can enter by opening a new EverBank Performance® Savings account or EverBank Performance® CD and funding it with at least $10,000 in new money—funds that do not originate from another EverBank account. That balance must then be maintained through
More news about: EverBank, N.A.